Nanostics: Molecular Monitoring in a Telemedicine Revolution
In an era where healthcare systems are increasingly under pressure, innovative solutions are paramount. DTU students Filip Angelov and Filip Furbu are at the forefront of this revolution, developing cutting-edge telemedicine hardware to monitor molecular biomarkers from the comfort of patients’ homes. This innovation aims to alleviate the burden on hospitals and improve patient outcomes by enabling early detection and intervention for complications.
The Problem and the Solution
Healthcare systems worldwide are grappling with an aging population and a rise in chronic diseases such as cancer and cardiovascular conditions. Traditional hospital stays for monitoring recovery are costly and often lead to readmissions. Angelof’s team identified a critical gap in telemedicine: the need for advanced hardware capable of monitoring a broader range of molecular biomarkers. Their solution is a novel device that allows continuous monitoring of patients’ health indicators, reducing the need for prolonged hospital stays and enabling timely medical interventions.
Bridging the Gap with Innovation
The team’s journey began with a deep dive into the limitations of current telemedicine technologies. While cardiac and glucose monitors have made significant strides, they are limited by existing hardware capabilities. Nanostics is developing an in-house solution that integrates both hardware and software, aiming to revolutionize telemedicine by providing comprehensive health monitoring tools.
|
Join the Health Innovators Program
The Health Innovators Program is a 4-month program targeted at early-stage start-ups and innovation ideas by students & teams who are motivated to develop solutions for better health. The programme is hosted by the Faculty of Health and Medical Science (UCPH) and Copenhagen Health Innovation – a collaboration between University of Copenhagen, University College Copenhagen, the Royal Academy, DTU and the Capital Region. |
Challenges and Milestones
Developing a medical technology startup is fraught with challenges, from regulatory hurdles to the need for substantial funding. Nanostics co-founders, who combine expertise in biomaterials and design innovation, have navigated these obstacles by building a robust team and securing initial funding. Their upcoming clinical trial marks a significant milestone, bringing them closer to their goal of transforming healthcare delivery.
The Road Ahead
As the team prepares for their clinical trial, they continue to refine their device through rapid iteration and testing. Their focus is not only on technical development but also on building a scalable business model. They aim to launch their product internationally, with plans for further funding rounds in Denmark and the US.
Advice for Aspiring Innovators
Angelof emphasizes the importance of identifying a real problem and validating the need for a solution. He encourages aspiring entrepreneurs to share their ideas and seek feedback early in the development process. Building a strong team and understanding the commercial landscape are also crucial for success.
Participation in Health Innovators Program
Angelof and his team have also benefited from their participation in the Health Innovators program, which has provided them with valuable insights and support in navigating the commercial and clinical landscape of healthcare innovation. This program has been instrumental in helping them refine their roadmap and connect with key stakeholders in the healthcare industry.
Ready to Improve Healthcare?
Have a desire to make healthcare better? Join the Health Innovators Programme and turn your ideas into reality. Applications are open now!
